SOX30 is a prognostic biomarker and chemotherapeutic ...
2
https://erc.bioscientifica.com © 2020 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. https://doi.org/10.1530/ERC-18-0529e 27:2 Endocrine-Related Cancer F Han, W Liu et al. SOX30 as a prognostic and chemotherapeutic marker X1–X2 ERRATUM SOX30 is a prognostic biomarker and chemotherapeutic indicator for advanced-stage ovarian cancer Fei Han 1, *, Wen-bin Liu 1, *, Jian-jun Li 2 , Ming-qian Zhang 3 , Jun-tang Yang 1 , Xi Zhang 1 , Xiang-lin Hao 1 , Li Yin 1 , Cheng-yi Mao 4 , Xiao Jiang 1 , Jia Cao 1 and Jin-yi Liu 1 1 Institute of Toxicology, College of Preventive Medicine, Army Medical University, Chongqing, China 2 Department of Oncology, Southwest Hospital, Army Medical University, Chongqing, China 3 Department of Emergency, Yan’an Hospital, Kunming Medical University, Kunming, Yunnan Province, China 4 Department of Pathology, Daping Hospital, Army Medical University, Chongqing, China Correspondence should be addressed to J Cao or J Liu: [email protected] or [email protected] *(F Han and W Liu contributed equally to this work) The authors and journal apologize for errors in the above paper, which appeared in volume 26 part 3, pages 303–319. The errors relate to the legend of Fig. 1A on page 307 and the artwork of Fig. 8D on page 316: 1) In the legend to Fig. 1A, the original text stated: ‘H represents high expression of SOX30 and the score ≤8 and ≤12. Scale bars represent 50 µm ...’ This should have stated: ‘H represents high expression of SOX30 and the score ≥8 and ≤12. Scale bars represent 50 µm …’ 2) In the artwork for Fig. 8D, the red data points labeled ‘6-Ovcar3-Vector+gemcitabine’ should have been labeled ‘6-Ovcar3-SOX30+gemcitabine’. The correct Fig. 8 is given in full below: Endocrine-Related Cancer (2020) 27, X1–X2 Downloaded from Bioscientifica.com at 03/17/2022 04:12:05AM via free access
Transcript of SOX30 is a prognostic biomarker and chemotherapeutic ...
https://erc.bioscientifica.com © 2020 Society for Endocrinology
Printed in Great BritainPublished by Bioscientifica Ltd.https://doi.org/10.1530/ERC-18-0529e
27:2Endocrine-Related Cancer
F Han, W Liu et al. SOX30 as a prognostic and chemotherapeutic marker
X1–X2
-18-0529e
ERRATUM
SOX30 is a prognostic biomarker and chemotherapeutic indicator for advanced-stage ovarian cancer
Fei Han1,*, Wen-bin Liu1,*, Jian-jun Li2, Ming-qian Zhang3, Jun-tang Yang1, Xi Zhang1, Xiang-lin Hao1, Li Yin1, Cheng-yi Mao4, Xiao Jiang1, Jia Cao1 and Jin-yi Liu1
1Institute of Toxicology, College of Preventive Medicine, Army Medical University, Chongqing, China2Department of Oncology, Southwest Hospital, Army Medical University, Chongqing, China3Department of Emergency, Yan’an Hospital, Kunming Medical University, Kunming, Yunnan Province, China4Department of Pathology, Daping Hospital, Army Medical University, Chongqing, China
Correspondence should be addressed to J Cao or J Liu: [email protected] or [email protected]
*(F Han and W Liu contributed equally to this work)
The authors and journal apologize for errors in the above paper, which appeared in volume 26 part 3, pages 303–319. The errors relate to the legend of Fig. 1A on page 307 and the artwork of Fig. 8D on page 316:
1) In the legend to Fig. 1A, the original text stated:‘H represents high expression of SOX30 and the score ≤8 and ≤12. Scale bars represent 50 µm ...’
This should have stated:‘H represents high expression of SOX30 and the score ≥8 and ≤12. Scale bars represent 50 µm …’
2) In the artwork for Fig. 8D, the red data points labeled ‘6-Ovcar3-Vector+gemcitabine’ should have been labeled ‘6-Ovcar3-SOX30+gemcitabine’. The correct Fig. 8 is given in full below:
Endocrine-Related Cancer (2020) 27, X1–X2
227
Downloaded from Bioscientifica.com at 03/17/2022 04:12:05AMvia free access
https://erc.bioscientifica.com © 2020 Society for Endocrinology
Printed in Great BritainPublished by Bioscientifica Ltd.https://doi.org/10.1530/ERC-18-0529e
27:2Endocrine-Related Cancer
F Han, W Liu et al. SOX30 as a prognostic and chemotherapeutic marker
X1–X2
Figure 8Different chemotherapy treatments combined with SOX30 expression influence tumor cell metastasis differently via EMT. (A) The migrated or invaded cells are analyzed by transwell assays in stable SOX30 or vector Ovcar3 cells treated with 3 µg/mL oxaliplatin. The migrated or invaded cells in the lower chamber are fixed, stained and determined by the average count of five random microscopic fields. Error bars indicate s.e.m. The P value is measured with Student’s t-tests. * represents P < 0.05. ** represents P < 0.01. NS represents non-statistical significance. (B) The migrated or invaded cells are measured by transwell assays in stable SOX30 or vector Ovcar3 cells treated with 45 µg/mL gemcitabine. Error bars indicate s.e.m. The P value is measured with Student’s t-tests. * represents P < 0.05. ** represents P < 0.01. (C) The expressions of N-CADHERIN and E-CADHERIN are significantly regulated, whereas SOX30 expression is not affected by chemotherapy drugs. β-Actin is used as an internal control. Error bars indicate s.e.m. The P value is measured with Student’s t-tests. ** represents P < 0.01. (D) Different chemotherapies combined with SOX30 expression influence the survival of xenograft nude mice differently. Survival and statistical significance are determined by Kaplan–Meier curves and log-rank test. (E) A schematic illustration of how SOX30 regulates tumor metastasis that is involved in chemotherapy treatments in ovarian cancer.
Downloaded from Bioscientifica.com at 03/17/2022 04:12:05AMvia free access
